<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3902178</article-id><article-id pub-id-type="publisher-id">18841</article-id><article-id pub-id-type="doi">10.7448/IAS.17.1.18841</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="20541" pm="."><plain>Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Abdurahman</surname><given-names>Samir</given-names></name><xref ref-type="corresp" rid="cor1">§</xref><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Barqasho</surname><given-names>Babilonia</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Nowak</surname><given-names>Piotr</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Cuong</surname><given-names>Do Duy</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Amogne</surname><given-names>Wondwossen</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Larsson</surname><given-names>Mattias</given-names></name><xref ref-type="aff" rid="AF0005">5</xref><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Lindquist</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Marrone</surname><given-names>Gaetano</given-names></name><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Sönnerborg</surname><given-names>Anders</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0002">2</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden</aff><aff id="AF0002"><label>2</label>Department of Medicine, Unit of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Sweden</aff><aff id="AF0003"><label>3</label>Infectious Diseases Department, Bach Mai Hospital, Hanoi, Vietnam</aff><aff id="AF0004"><label>4</label>Department of Medicine, Faculty of Medicine, Addis Ababa University, Ethiopia</aff><aff id="AF0005"><label>5</label>Division of Global Health (IHCAR), Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden</aff><aff id="AF0006"><label>6</label>Oxford University Clinical Research Unit (OUCRU), Hanoi, Vietnam</aff><author-notes><corresp id="cor1"><label>§</label><bold>Corresponding author:</bold> Samir Abdurahman, Division of Clinical Microbiology, Department of Laboratory Medicine, F68, Karolinska University Hospital Huddinge, SE-14186 Stockholm, Sweden. Tel: +46 8 585 81338, Fax: +46 8 585 87933. (<email xlink:href="Samir.abdurahman@ki.se">Samir.abdurahman@ki.se</email>)</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>1</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>1</issue><elocation-id content-type="doi">18841</elocation-id><history><date date-type="received"><day>23</day><month>8</month><year>2013</year></date><date date-type="rev-recd"><day>23</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>© 2014 Abdurahman S et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><text><SENT sid="20542" pm="."><plain>Introduction </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="20543" pm="."><plain>The role of microbial translocation (MT) in HIV patients living with HIV from low- and middle-income countries (LMICs) is not fully known. </plain></SENT>
<SENT sid="20544" pm="."><plain>The aim of this study is to investigate and compare the patterns of MT in patients from Vietnam, Ethiopia and Sweden. </plain></SENT>
</text></SecTag></p></sec><sec id="st2"><title><text><SENT sid="20545" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="20546" pm="."><plain>Cross-sectional samples were obtained from treatment-naïve patients living with HIV-1 and healthy controls from Vietnam (n=83; n=46), Ethiopia (n=9492; n=50) and Sweden (n=51; n=19). </plain></SENT>
<SENT sid="20547" pm="."><plain>Longitudinal samples were obtained from a subset of the Vietnamese (n=24) in whom antiretroviral therapy (ART) and tuberculostatics were given. </plain></SENT>
<SENT sid="20548" pm="."><plain>Plasma lipopolysaccharide (LPS), sCD14 and anti-flagellin IgG were determined by the endpoint chromogenic Limulus Amebocyte Assay and enzyme-linked immunosorbent assay. </plain></SENT>
</text></SecTag></p></sec><sec id="st3"><title><text><SENT sid="20549" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="20550" pm="."><plain>All three biomarkers were significantly increased in patients living with HIV-1 from all countries as compared to controls. </plain></SENT>
<SENT sid="20551" pm="."><plain>No differences were found between males and females. </plain></SENT>
<SENT sid="20552" pm="."><plain>Vietnamese and Ethiopian patients had significantly higher levels of anti-flagellin IgG and LPS, as compared to Swedes. </plain></SENT>
<SENT sid="20553" pm="."><plain>ART reduced these levels for the Vietnamese. </plain></SENT>
<SENT sid="20554" pm="."><plain>Vietnamese patients given tuberculostatics at initiation of ART had significantly lower levels of anti-flagellin IgG and higher sCD14. </plain></SENT>
<SENT sid="20555" pm="."><plain>The biomarkers were lower in Vietnamese who did not develop opportunistic infection. </plain></SENT>
</text></SecTag></p></sec><sec id="st4"><title><text><SENT sid="20556" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="20557" pm="."><plain>Higher MT is common in patients living with HIV compared to healthy individuals, and in patients from LMICs compared to patients from a high-income country. </plain></SENT>
<SENT sid="20558" pm="."><plain>Treatment with tuberculostatics decreased MT while higher levels of MT are associated with a poorer clinical outcome. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group><kwd>microbial translocation</kwd><kwd>immune activation</kwd><kwd>LPS</kwd><kwd>sCD14</kwd><kwd>treatment-naïve patients living with HIV</kwd><kwd>HIV in Vietnam</kwd><kwd>HIV in Ethiopia</kwd><kwd>HIV in Sweden</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="S0001"><title><text><SENT sid="20559" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="20560" pm="."><plain>Gut–blood barrier dysfunction is a hallmark of human immunodeficiency virus type 1 (HIV-1) infection. </plain></SENT>
<SENT sid="20561" pm="."><plain>It is associated with translocation of microbial products, thereby contributing to the systemic immune activation seen in patients living with HIV-1 [1, 2]. </plain></SENT>
<SENT sid="20562" pm="."><plain>In diseases such as Crohn’s disease and ulcerative colitis, bacterial flagellin has been pinpointed to be of major pathogenetic importance, and high plasma levels of immunoglobulins (IgG) directed towards this bacterial antigen are present [3–5]. </plain></SENT>
<SENT sid="20563" pm="."><plain>We and others have reported increased plasma levels of microbial translocated products in patients living with HIV-1 who live in high-income countries, which decrease during antiretroviral therapy (ART) [6, 7]. </plain></SENT>
<SENT sid="20564" pm="."><plain>Also, we have suggested that various drug combinations may have different outcomes in terms of improvement of the microbial translocation (MT) markers in patients living with HIV-1 [8]. </plain></SENT>
<SENT sid="20565" pm="."><plain>In contrast, the role of MT in the HIV epidemic in low- and middle-income countries (LMICs) remains controversial and not well studied. </plain></SENT>
<SENT sid="20566" pm="."><plain>It has been suggested that MT is important for HIV disease progression in Africa [9], but this has been disputed [10]. </plain></SENT>
<SENT sid="20567" pm="."><plain>Also, increased MT has been reported in South African subjects before ART, but it remained elevated during efficient therapy [11]. </plain></SENT>
</text></p><p><text><SENT sid="20568" pm="."><plain>In order to obtain more knowledge about MT in LMICs, we sought to evaluate to which extent Vietnamese and Ethiopian patients living with HIV-1 demonstrate higher levels of biomarkers for MT and if efficient ART influenced these levels in the Vietnamese patients. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="S0002"><title><text><SENT sid="20569" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="S0002-S20001"><title><text><SENT sid="20570" pm="."><plain>Study populations </plain></SENT>
</text></title><p><text><SENT sid="20571" pm="."><plain>The study populations were obtained from three countries: Vietnam, Ethiopia and Sweden (Table 1). </plain></SENT>
<SENT sid="20572" pm="."><plain>The Vietnamese patients were part of a prospective, longitudinal study, and detailed clinical information as well as follow-up samples were available. </plain></SENT>
<SENT sid="20573" pm="."><plain>The blood samples were drawn before starting ART and at 24 months after initiation of ART. </plain></SENT>
<SENT sid="20574" pm="."><plain>For the Ethiopian patients, only a cross-sectional analysis was performed due to the lack of follow-up data. </plain></SENT>
<SENT sid="20575" pm="."><plain>Swedish patients were analyzed in a cross-sectional fashion for comparison with the Vietnamese and Ethiopian patients. </plain></SENT>
<SENT sid="20576" pm="."><plain>Both the Ethiopians and the Swedes were untreated. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p><text><SENT sid="20577" pm="."><plain>Characteristics of Vietnamese, Ethiopian and Swedish patients living with HIV-1 </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="20578" pm="."><plain>Characteristics </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="20579" pm="."><plain>Vietnamese patients </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="20580" pm="."><plain>Ethiopian patients </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="20581" pm="."><plain>Swedish patients </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="20582" pm="."><plain>pa </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20583" pm="."><plain>N </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20584" pm="."><plain>83 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20585" pm="."><plain>92 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20586" pm="."><plain>51 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20587" pm="."><plain>– </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20588" pm="."><plain>Age (years) (median, IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20589" pm="."><plain>35 (32–38) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20590" pm="."><plain>35 (29–41) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20591" pm="."><plain>38 (30–46) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20592" pm="."><plain>0.044 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20593" pm="."><plain>Sex (n) (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20594" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20595" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20596" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20597" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20598" pm="."><plain> Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20599" pm="."><plain>19 (23) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20600" pm="."><plain>65 (70) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20601" pm="."><plain>26 (48) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20602" pm="."><plain>– </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20603" pm="."><plain> Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20604" pm="."><plain>64 (77) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20605" pm="."><plain>27 (30) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20606" pm="."><plain>25 (52) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20607" pm="."><plain>– </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20608" pm="."><plain>Baseline CD4+ T-cells (cells/µl) (median, IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20609" pm="."><plain>64 (24–169) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20610" pm="."><plain>100 (56–144) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20611" pm="."><plain>212 (138–280) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20612" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20613" pm="."><plain>Baseline HIV viral load [log10 copies/ml (median, IQR)] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20614" pm="."><plain>4.8 (4.3–5.3) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20615" pm="."><plain>5.4 (5.0–5.8) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20616" pm="."><plain>5.4 (5.0–5.8) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20617" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20618" pm="."><plain>BMI (kg/m2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20619" pm="."><plain>19 (18–20) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20620" pm="."><plain>20 (18–23) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20621" pm="."><plain>ND </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20622" pm="."><plain>0.005 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20623" pm="."><plain>Mode of HIV infection (n) (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20624" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20625" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20626" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20627" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20628" pm="."><plain> Heterosexual </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20629" pm="."><plain>31 (37) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20630" pm="."><plain>92 (100) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20631" pm="."><plain>34 (67) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20632" pm="."><plain>– </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20633" pm="."><plain> Homosexual </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20634" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20635" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20636" pm="."><plain>10 (19) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20637" pm="."><plain>– </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20638" pm="."><plain> Injecting drug use </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20639" pm="."><plain>38 (46) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20640" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20641" pm="."><plain>4 (8) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20642" pm="."><plain>– </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20643" pm="."><plain> Others or unknown </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20644" pm="."><plain>14 (17) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20645" pm="."><plain>– </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20646" pm="."><plain>3 (6) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20647" pm="."><plain>– </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="TF0001"><label>a</label><p><text><SENT sid="20648" pm="."><plain>Kruskal–Wallis, Wilcoxon rank sum or chi-squared test as appropriate. </plain></SENT>
<SENT sid="20649" pm="."><plain>IQR, interquartile range; ND, not done; BMI, body mass index. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="20650" pm="."><plain>The Vietnamese patients (n=83) (Table 1) were randomly selected from a larger number of subjects (n=640) who were part of a randomized controlled trial in northeastern Vietnam between 2008 and 2011, which assessed the effect of peer support on treatment failure (registration number: NCT01433601) [12]. </plain></SENT>
<SENT sid="20651" pm="."><plain>The selected 83 patients had similar demographic and laboratory characteristics as the whole cohort (data not shown). </plain></SENT>
<SENT sid="20652" pm="."><plain>Twenty-four subjects had ongoing tuberculosis (TB) diagnosed two months before inclusion in the study and had been given tuberculostatics for two months (rifampicin, isoniazid, ethambutol and pyrazinamide), with an efficient therapeutic response to the TB therapy, before starting ART [stavudine (d4T) or zidovudine (ZDV) plus lamivudine (3TC) plus nevirapine (NVP) or efavirenz (EFV)]. </plain></SENT>
<SENT sid="20653" pm="."><plain>In six of these subjects, treatment continued for an additional ten months, while remaining 18 subjects received only six months of treatment (isoniazid and ethambutol). </plain></SENT>
<SENT sid="20654" pm="."><plain>Clinical information for all subjects was obtained from their physician during follow-up. </plain></SENT>
<SENT sid="20655" pm="."><plain>All patients had undetectable HIV load at 24-month follow-up. </plain></SENT>
<SENT sid="20656" pm="."><plain>Plasma samples were drawn before ART and in 38 cases at 24-month follow-up, and they were thereafter stored at −80°C. </plain></SENT>
<SENT sid="20657" pm="."><plain>Samples were also obtained from 46 healthy Vietnamese HIV-negative controls who originated from the same socioeconomic grouping and geographical area. </plain></SENT>
</text></p><p><text><SENT sid="20658" pm="."><plain>Plasma samples were also obtained from 92 treatment-naïve Ethiopian patients living with HIV-1 (Table 1) from three different health care centres in Addis Ababa. </plain></SENT>
<SENT sid="20659" pm="."><plain>The patients had been assessed clinically by an experienced physician. </plain></SENT>
<SENT sid="20660" pm="."><plain>No signs of TB had been found and no TB treatment had been given. </plain></SENT>
<SENT sid="20661" pm="."><plain>Fifty healthy HIV-negative Ethiopian controls who were matched with regard to socioeconomics, age and sex, all living in Addis Ababa in the same geographical region, were included as controls. </plain></SENT>
<SENT sid="20662" pm="."><plain>No follow-up data with clinical information or follow-up samples were available. </plain></SENT>
<SENT sid="20663" pm="."><plain>From Sweden, 51 treatment-naïve patients living with HIV-1 followed at Karolinska University Hospital were included for comparative purposes (Table 1) along with 19 healthy HIV-negative Caucasian Swedish individuals, all living in the capital city of Stockholm with a good socioeconomic situation. </plain></SENT>
<SENT sid="20664" pm="."><plain>The samples had been stored at −80°C until use. </plain></SENT>
<SENT sid="20665" pm="."><plain>None of patients living in Sweden had an ongoing TB infection as determined by chest X-ray and standard clinical investigations. </plain></SENT>
</text></p><p><text><SENT sid="20666" pm="."><plain>The study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Ethics Committee in Stockholm, Sweden; the Institutional Review Board of Addis Ababa University, Ethiopia; and the Hanoi Medical University Review Board in Bio-medical research, Vietnam. </plain></SENT>
</text></p></sec><sec id="S0002-S20002"><title><text><SENT sid="20667" pm="."><plain>Anti-flagellin enzyme-linked immunosorbent assay (ELISA) </plain></SENT>
</text></title><p><text><SENT sid="20668" pm="."><plain>An in-house ELISA was developed for the detection of plasma anti-flagellin IgG antibodies. </plain></SENT>
<SENT sid="20669" pm="."><plain>High-binding 96-well microwell plates (MWPs) (Costar) were coated with purified flagellin monomers from S. typhimurium and incubated overnight at 4°C. </plain></SENT>
<SENT sid="20670" pm="."><plain>The MWPs were washed and blocked with 1% bovine serum albumin in phosphate-buffered saline (PBS) at room temperature for 1 h. </plain></SENT>
<SENT sid="20671" pm="."><plain>Plasma samples (diluted 1:1000 in PBS) were added to the plates and incubated at room temperature for 2 h. </plain></SENT>
<SENT sid="20672" pm="."><plain>The MWPs were washed and horseradish peroxidase-conjugated anti-human antibody (1:20,000) was added before being incubated further at room temperature for 1 h. </plain></SENT>
<SENT sid="20673" pm="."><plain>Finally, the MWPs were washed and the plates were read in a Labsystems multiscan MCC 340 spectrophotometer. </plain></SENT>
</text></p></sec><sec id="S0002-S20003"><title><text><SENT sid="20674" pm="."><plain>Detection of lipopolysaccharide (LPS) and sCD14 </plain></SENT>
</text></title><p><text><SENT sid="20675" pm="."><plain>Plasma LPS levels were determined using the endpoint chromogenic Limulus Amebocyte Assay (Lonza, Walkersville, MD, USA), essentially as described in the manufacturer’s protocol except that the samples were diluted 1:5 in an endotoxin-free 10 mM MgCl2 solution and inactivated for 12 min in 70°C using an endotoxin-free glass tubes. </plain></SENT>
<SENT sid="20676" pm="."><plain>A commercial ELISA kit (R&amp;D Systems, Inc., Minneapolis, MN, USA) was used to measure plasma concentrations of soluble CD14 according to the manufacturer′s recommendations. </plain></SENT>
</text></p></sec><sec id="S0002-S20004"><title><text><SENT sid="20677" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="20678" pm="."><plain>Due to the non-normal distribution of the outcomes of interest (anti-flagellin IgG levels, LPS and sCD14), the non-parametric Mann–Whitney U test was used to compare median differences between patients and controls at baseline. </plain></SENT>
<SENT sid="20679" pm="."><plain>Intragroup changes from baseline to the end of the study were analyzed by a Wilcoxon test for paired samples. </plain></SENT>
<SENT sid="20680" pm="."><plain>Comparisons of more than two groups were performed using the Kruskal–Wallis non-parametric test. </plain></SENT>
<SENT sid="20681" pm="."><plain>All tests had a 95% confidence level. </plain></SENT>
<SENT sid="20682" pm="."><plain>Correlations between the outcomes and the CD4+ T-cell count, viral load, age, sex, route of infection and body mass index (BMI) were calculated using Spearman’s rank correlation coefficient. </plain></SENT>
</text></p><p><text><SENT sid="20683" pm="."><plain>Multivariable linear regression models with bootstrap confidence intervals in order to take into account the non-linearity of the outcomes (tested by the Shapiro–Wilk test for normality) were used to compare baseline differences in anti-flagellin IgG, sCD14 and LPS levels between Vietnamese, Ethiopian and Swedish patients living with HIV-1. </plain></SENT>
<SENT sid="20684" pm="."><plain>Factors considered in the regression model were also age, sex and baseline CD4+ T-cell count. </plain></SENT>
<SENT sid="20685" pm="."><plain>GraphPad Prism software, version 5.04 (GraphPad Software Inc., San Diego, CA, USA) and Stata (Stata Corporation, College Station, TX, USA) were used for these analyses. P-values &lt;0.05 were considered significant. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="S0003"><title><text><SENT sid="20686" pm="."><plain>Results </plain></SENT>
</text></title><sec id="S0003-S20001"><title><text><SENT sid="20687" pm="."><plain>Anti-flagellin IgG levels in Vietnamese patients </plain></SENT>
</text></title><p><text><SENT sid="20688" pm="."><plain>All Vietnamese subjects (n=83) had detectable plasma anti-flagellin IgG. </plain></SENT>
<SENT sid="20689" pm="."><plain>At baseline, the levels were higher in these ART-naïve patients living with HIV-1 as compared with the HIV-negative controls [median optical density (OD): 0.76 (IQR 0.55–1.34) versus 0.32 (IQR 0.25–0.53); p&lt;0.001] (Figure 1A). </plain></SENT>
<SENT sid="20690" pm="."><plain>In the patients (n=38) in whom follow-up samples were available, the anti-flagellin IgG were reduced by two years of ART to similar levels [median OD: 0.40 (IQR 0.33–0.45); p&lt;0.001] as in the controls. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F0001" position="float"><label>Figure 1</label><caption><p><text><SENT sid="20691" pm="."><plain>Detection of plasma anti-flagellin IgG, lipopolysaccharide (LPS) and soluble CD14 (sCD14) in Vietnamese patients living with HIV-1 and in HIV-negative controls. </plain></SENT>
<SENT sid="20692" pm="."><plain>Box plot representing the plasma levels of anti-flagellin IgG (A), the ratio of flagellin-specific IgG to total IgG (B), LPS (C) and sCD14 (D) in healthy controls (Controls), naïve individuals living with HIV-1 (Naïve) and individuals living with HIV-1 after 24 months of antiretroviral therapy (ART). </plain></SENT>
<SENT sid="20693" pm="."><plain>Box plots display the median OD value and 25th and 75th interquartile ranges. </plain></SENT>
<SENT sid="20694" pm="."><plain>Whiskers represent the 5th to 95th percentiles, and dots the outliers. </plain></SENT>
<SENT sid="20695" pm="."><plain>The non-parametric Mann-Whitney test was used to compare the differences between patients and controls at baseline. </plain></SENT>
<SENT sid="20696" pm="."><plain>The intragroup change from baseline to the end of the follow-up study was analyzed by a Wilcoxon test. </plain></SENT>
</text></p></caption><graphic xlink:href="JIAS-17-18841-g001"/></fig></SecTag><p><text><SENT sid="20697" pm="."><plain>Similar statistically significant differences in the total IgG levels were observed (data not shown). </plain></SENT>
<SENT sid="20698" pm="."><plain>When the flagellin-specific IgG were adjusted to the total IgG, the differences between the patients living with HIV-1 at baseline and the controls persisted [median OD: 0.46 (IQR 0.34–0.82) versus 0.37 (IQR 0.28–0.60); p=0.01] (Figure 1B). </plain></SENT>
<SENT sid="20699" pm="."><plain>There was no significant correlation between anti-flagellin IgG with CD4+ T-cell count, viral load, sex, route of infection or BMI. </plain></SENT>
<SENT sid="20700" pm="."><plain>A weak correlation was found with age (r=0.28, p=0.01). </plain></SENT>
</text></p></sec><sec id="S0003-S20002"><title><text><SENT sid="20701" pm="."><plain>LPS and sCD14 levels in Vietnamese patients </plain></SENT>
</text></title><p><text><SENT sid="20702" pm="."><plain>At baseline, the plasma LPS and sCD14 levels were higher in the Vietnamese patients living with HIV-1 as compared to the healthy Vietnamese controls [LPS, median pg/ml: 211 (IQR 190–232) versus 163 (IQR 153–185); sCD14, median pg/ml: 4,535,000 (IQR 3,237,000–5,898,000) versus 2,093,000 (IQR 1,577,000–2,724,000); p&lt;0.0001 for both] (Figure 1C and 1D). </plain></SENT>
<SENT sid="20703" pm="."><plain>The levels of LPS and sCD14 were reduced following two years of ART [LPS, median pg/ml: 182 (IQR 166–203); sCD14, median pg/ml: 2,116,000 (IQR 1,885,000–2,632,000); p&lt;0.0001 for both], although the LPS level was not normalized and remained slightly higher than in the controls [median pg/ml: 163 (IQR 153–185); p=0.004] (Figure 1C and 1D). </plain></SENT>
<SENT sid="20704" pm="."><plain>No correlation was found between the levels of LPS and sCD14 and CD4+ T-cell counts, viral load, age, sex, route of infection or BMI, respectively. </plain></SENT>
</text></p></sec><sec id="S0003-S20003"><title><text><SENT sid="20705" pm="."><plain>Anti-flagellin IgG, LPS and sCD14 in TB-treated Vietnamese patients </plain></SENT>
</text></title><p><text><SENT sid="20706" pm="."><plain>Twenty-four of the Vietnamese participants had received TB treatment for two months prior to starting ART (Table 2). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p><text><SENT sid="20707" pm="."><plain>Characteristics of Vietnamese patients living with HIV-1, with and without tuberculosis (TB) treatment, at baseline </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="20708" pm="."><plain>Characteristics </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="20709" pm="."><plain>Patients with TB </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="20710" pm="."><plain>Patients without TB </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20711" pm="."><plain>N </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20712" pm="."><plain>24 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20713" pm="."><plain>59 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20714" pm="."><plain>Age (years) (median, IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20715" pm="."><plain>34 (31–39) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20716" pm="."><plain>35 (33–38) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20717" pm="."><plain>Sex (n) (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20718" pm="."><plain> Female </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20719" pm="."><plain>3 (13) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20720" pm="."><plain>13 (22) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20721" pm="."><plain> Male </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20722" pm="."><plain>21 (87) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20723" pm="."><plain>46 (78) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20724" pm="."><plain>Baseline CD4+ T-cells (cells/µl) (median, IQR) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20725" pm="."><plain>49 (23–103) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20726" pm="."><plain>79 (23–174) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20727" pm="."><plain>Baseline HIV viral load [log10 copies/ml (median, IQR)] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20728" pm="."><plain>4.6 (4.4–5.3) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20729" pm="."><plain>4.7 (4.2–5.2) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20730" pm="."><plain>BMI (kg/m2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20731" pm="."><plain>19 (17–20) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20732" pm="."><plain>19 (18–20) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20733" pm="."><plain>Hemoglobin (g/dL) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20734" pm="."><plain>131 (118–143) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20735" pm="."><plain>127 (110–140) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20736" pm="."><plain>Mode of HIV infection (n) (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20737" pm="."><plain> Heterosexual </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20738" pm="."><plain>6 (25) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20739" pm="."><plain>20 (38) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20740" pm="."><plain> Injecting drug use </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20741" pm="."><plain>15 (63) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20742" pm="."><plain>21 (41) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20743" pm="."><plain> Others or unknown </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20744" pm="."><plain>3 (12) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20745" pm="."><plain>11 (21) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="20746" pm="."><plain>TB, tuberculosis; IQR, interquartile range; BMI, body mass index. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="20747" pm="."><plain>The level of anti-flagellin IgG was significantly lower in these subjects as compared to those (n=59) without TB treatment [median OD: 0.48 (IQR 0.37–0.88) versus 0.74 (IQR 0.53–1.36); p&lt;0.01] (Figure 2A). </plain></SENT>
<SENT sid="20748" pm="."><plain>The level of anti-flagellin IgG in the TB-treated patients was still significantly higher than in the controls [median OD: 0.32 (IQR 0.25–0.53); p=0.004]. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F0002" position="float"><label>Figure 2</label><caption><p><text><SENT sid="20749" pm="."><plain>Baseline characteristics of patients living with HIV-1 with and without ongoing tuberculosis (TB) treatment. </plain></SENT>
<SENT sid="20750" pm="."><plain>OD values representing the plasma levels of anti-flagellin IgG (A), LPS (B) and sCD14 (C) in healthy controls (Controls), and naïve individuals living with HIV-1 with (TB) and without (No TB) treatment for TB. </plain></SENT>
<SENT sid="20751" pm="."><plain>Box plots display the median OD value and 25th and 75th interquartile ranges. </plain></SENT>
<SENT sid="20752" pm="."><plain>Whiskers represent the 5th to 95th percentiles, and dots the outliers. </plain></SENT>
<SENT sid="20753" pm="."><plain>Pairwise comparisons refer to a Mann-Whitney test. </plain></SENT>
</text></p></caption><graphic xlink:href="JIAS-17-18841-g002"/></fig></SecTag><p><text><SENT sid="20754" pm="."><plain>The level of LPS was lower in the TB-treated patients as compared to those without [median pg/ml: 201 (IQR 169–250) versus 213 (IQR 196–231), respectively], although it was not statistically significant (Figure 2B). </plain></SENT>
<SENT sid="20755" pm="."><plain>Also, the level of LPS in patients given TB treatment was significantly higher than in the controls [median pg/ml: 164 (IQR 153–185); p&lt;0.001]. </plain></SENT>
</text></p><p><text><SENT sid="20756" pm="."><plain>In contrast, the level of sCD14 was significantly higher in TB-treated patients as compared to those without [median pg/ml: 517,100 (IQR 393,200–615,400) vs. 402,400 (IQR 315,000–556,500); p=0.048] as well as compared to the controls [209,300 pg/ml (IQR 157,700–272,400); p&lt;0.001] (Figure 2C). </plain></SENT>
<SENT sid="20757" pm="."><plain>There were no statistically significant differences between men and women in terms of anti-flagellin (p=0.5613), LPS (p=0.5805) or sCD14 (p=0.6798) levels. </plain></SENT>
</text></p></sec><sec id="S0003-S20004"><title><text><SENT sid="20758" pm="."><plain>Anti-flagellin IgG, LPS and sCD14 in Vietnamese patients developing opportunistic infections </plain></SENT>
</text></title><p><text><SENT sid="20759" pm="."><plain>The baseline levels of anti-flagellin IgG, LPS and sCD14 were compared between the Vietnamese patients who developed one or more opportunistic infections (OIs) and survived (n=27), those who developed a new OI and died (n=11) and those who did not develop OIs during follow-up (n=45) (data not shown). </plain></SENT>
<SENT sid="20760" pm="."><plain>Patients who had TB treatment at baseline were categorized in the non-OI group (n=10), deaths (n=9) or a new OI (n=14). </plain></SENT>
</text></p><p><text><SENT sid="20761" pm="."><plain>The levels of all three markers were significantly higher in the patients who developed OI and survived, as well as in those who did not develop OI, as compared to the controls (Figure 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F0003" position="float"><label>Figure 3</label><caption><p><text><SENT sid="20762" pm="."><plain>Baseline markers in Vietnamese patients living with HIV-1 with and without new opportunistic infection (OI) development during antiretroviral treatment (ART). </plain></SENT>
<SENT sid="20763" pm="."><plain>Box plot of OD values representing the plasma levels of anti-flagellin IgG (A), LPS (B) and sCD14 (C) concentrations in naïve Vietnamese patients living with HIV-1 who died (Dead), and those with (OI) or without (No OI) the development of OI. </plain></SENT>
<SENT sid="20764" pm="."><plain>Box plots display the median value and 25th and 75th interquartile ranges. </plain></SENT>
<SENT sid="20765" pm="."><plain>Whiskers represent the 5th to 95th percentiles, and dots the outliers. </plain></SENT>
<SENT sid="20766" pm="."><plain>Pairwise comparisons refer to a Mann–Whitney U test. </plain></SENT>
</text></p></caption><graphic xlink:href="JIAS-17-18841-g003"/></fig></SecTag><p><text><SENT sid="20767" pm="."><plain>Also, the levels of anti-flagellin IgG, LPS and sCD14 were significantly higher in patients who developed a new OI and survived as compared to those who did not develop an OI [anti-flagellin IgG, median OD: 0.85 (IQR 0.61–1.34) vs. 0.65 (IQR 0.48–1.16); p=0.023; LPS, median pg/ml: 218 (IQR 196–236) vs. 206 (IQR 169–230); p=0.032; sCD14, median pg/ml: 5,116,000 (IQR 3,595,000–6,198,000) vs. 4,188,000 (IQR 3,172,000–5,500,000); p=0.047] (Figure 3C). </plain></SENT>
<SENT sid="20768" pm="."><plain>We found no statistically significant differences in terms of all three markers between TB/HIV co-infected patients as compared to patients with HIV alone, when charted separately (data not shown). </plain></SENT>
<SENT sid="20769" pm="."><plain>However, patients with TB (and anti-bacterial therapy) had higher risk of developing OI as compared to patients without TB. </plain></SENT>
</text></p><p><text><SENT sid="20770" pm="."><plain>In the patients who died, the level of anti-flagellin IgG was not significantly different from that of patients with or without OI, and the levels of LPS were in fact significantly lower as compared to those of patients with (p=0.004) or without (p=0.049) OI (Figure 3A and 3B). </plain></SENT>
<SENT sid="20771" pm="."><plain>In contrast, the sCD14 levels in patients who died were significantly higher as compared to those of the patients without OI [median pg/ml: 5,459,000 (IQR 4,038,000–6,834,000) versus 4,188,000 (IQR 3,172,000–5,500,000); p=0.020]. </plain></SENT>
<SENT sid="20772" pm="."><plain>However, there was no significant difference as compared to patients with OI [median pg/ml 4,188,000 (IQR 3,172,000–5,500,000); p=0.310]. </plain></SENT>
<SENT sid="20773" pm="."><plain>We found no statistically significant differences of anti-flagellin (p=0.1322), LPS (p=0.4350) or sCD14 (p=0.3636) levels between men and women with OI. </plain></SENT>
</text></p></sec><sec id="S0003-S20005"><title><text><SENT sid="20774" pm="."><plain>HIV load and CD4+ T-cells in Vietnamese patients </plain></SENT>
</text></title><p><text><SENT sid="20775" pm="."><plain>Plasma viral load was significantly higher in the 11 patients who died as compared to the patients with OI who survived and those without OI, respectively [median copies/ml: 230,000 (IQR 82,108–290,000) vs. 82,108 (IQR 29,950–221,848) vs. 37,022 (IQR 15,868–122,570); p=0.026, p=0.006, respectively]. </plain></SENT>
<SENT sid="20776" pm="."><plain>The level of CD4+ T-cells was lower in patients who died as compared to patients without OI [median cells/ml: 29 (IQR 12–77) vs. 140 (IQR 56–199); p&lt;0.001], but not different from that of patients with OI (data not shown). </plain></SENT>
</text></p></sec><sec id="S0003-S20006"><title><text><SENT sid="20777" pm="."><plain>Comparisons between Vietnamese, Ethiopian and Swedish patients living with HIV-1 </plain></SENT>
</text></title><p><text><SENT sid="20778" pm="."><plain>We compared the level of anti-flagellin IgG, LPS and sCD14 between Vietnamese, Ethiopian and Swedish treatment-naïve patients living with HIV-1 (Figure 4 and Table 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F0004" position="float"><label>Figure 4</label><caption><p><text><SENT sid="20779" pm="."><plain>Baseline anti-flagellin antibody levels in treatment-naïve Vietnamese, Ethiopian and Swedish patients living with HIV-1. </plain></SENT>
<SENT sid="20780" pm="."><plain>Box plot of OD values representing the levels of anti-flagellin antibodies (A), plasma sCD14 (B) and LPS (C) concentrations in treatment-naïve Vietnamese, Ethiopian and Swedish patients living with HIV-1. </plain></SENT>
<SENT sid="20781" pm="."><plain>Box plots display the median value and 25th and 75th interquartile ranges. </plain></SENT>
<SENT sid="20782" pm="."><plain>Whiskers represent the 5th to 95th percentiles, and dots the outliers. </plain></SENT>
<SENT sid="20783" pm="."><plain>Pairwise comparisons refer to a Mann-Whitney U test. </plain></SENT>
</text></p></caption><graphic xlink:href="JIAS-17-18841-g004"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T0003" position="float"><label>Table 3</label><caption><p><text><SENT sid="20784" pm="."><plain>Regression models with bootstrap confidence interval to compare baseline differences in anti-flagellin IgG, sCD14 and LPS levels between Vietnamese, Ethiopian and Swedish patients living with HIV-1 who had no clinical signs of tuberculosis </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="20785" pm="."><plain>Outcome </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="20786" pm="."><plain>Coefficient (95% CI) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="20787" pm="."><plain>p </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20788" pm="."><plain>Anti-flagellin IgG </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20789" pm="."><plain> Sweden </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20790" pm="."><plain>Ref. </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20791" pm="."><plain> Ethiopia </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20792" pm="."><plain>0.56 (0.39–0.74) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20793" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20794" pm="."><plain> Vietnam </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20795" pm="."><plain>0.39 (0.16–0.61) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20796" pm="."><plain>&lt;0.01 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20797" pm="."><plain>sCD14 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20798" pm="."><plain> Sweden </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20799" pm="."><plain>Ref. </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20800" pm="."><plain> Ethiopia </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20801" pm="."><plain>511,685 (33,864–989,505) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20802" pm="."><plain>&lt;0.05 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20803" pm="."><plain> Vietnam </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20804" pm="."><plain>2,342,364 (1,675,132–3,009,597) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20805" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20806" pm="."><plain>LPS </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20807" pm="."><plain> Sweden </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20808" pm="."><plain>Ref. </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20809" pm="."><plain> Ethiopia </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20810" pm="."><plain>139 (119–158) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20811" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="20812" pm="."><plain> Vietnam </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20813" pm="."><plain>147 (126–168) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="20814" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="20815" pm="."><plain>Results adjusted by CD4 at baseline, age and sex. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="20816" pm="."><plain>In all groups, the levels of anti-flagellin IgG, LPS and sCD14 were significantly higher than in matched HIV-negative controls (data not shown; p&lt;0.001 for all). </plain></SENT>
<SENT sid="20817" pm="."><plain>When baseline anti-flagellin IgG levels were compared between the groups using a bivariate analysis, the level in Swedish patients was lower than in both Vietnamese and Ethiopian patients living with HIV (p&lt;0.0001 for both). </plain></SENT>
<SENT sid="20818" pm="."><plain>Vietnamese patients also had lower levels of anti-flagellin IgG as compared to Ethiopian patients (p=0.007) (Figure 4A). </plain></SENT>
<SENT sid="20819" pm="."><plain>In contrast, sCD14 levels in Vietnamese patients were higher than in both Swedish and Ethiopian patients living with HIV (p&lt;0.0001 for both). </plain></SENT>
<SENT sid="20820" pm="."><plain>The sCD14 levels were higher in Ethiopians as compared to Swedish patients (p&lt;0.0001). </plain></SENT>
<SENT sid="20821" pm="."><plain>In terms of LPS levels, there was no statistically significant difference between Vietnamese and Ethiopian patients; Swedish patients living with HIV-1 had significantly lower levels of LPS as compared to Vietnamese and Ethiopian patients (p&lt;0.0001 for both). </plain></SENT>
</text></p><p><text><SENT sid="20822" pm="."><plain>In the multivariable analysis, the age, sex and CD4+ T-cell adjusted differences in all three markers between the groups still persisted, except for the sCD14 differences between Swedish and Ethiopians. </plain></SENT>
<SENT sid="20823" pm="."><plain>The estimated anti-flagellin IgG levels were higher in Vietnamese (p&lt;0.0001) and Ethiopian (p&lt;0.0001) patients as compared to the Swedes. </plain></SENT>
<SENT sid="20824" pm="."><plain>The Swedish patients were chosen as a reference category, because the Ethiopian patients had a significantly higher expected value of anti-flagellin antibodies (Coeff.=0.54, 95% CI: 0.37–0.72), as did the Vietnamese patients (Coeff.=0.43, 95% CI: 0.20–0.67). </plain></SENT>
<SENT sid="20825" pm="."><plain>The estimated sCD14 levels were significantly higher in Vietnamese patients (p&lt;0.0001, Coeff.=2,344,373, 95% CI: 1,778,541–2,910,204) as compared to the Swedes. </plain></SENT>
<SENT sid="20826" pm="."><plain>In contrast, the sCD14 difference between the Swedish and Ethiopian groups was lost and was not statistically significant upon multivariate analysis. </plain></SENT>
<SENT sid="20827" pm="."><plain>In terms of the LPS, the levels were still significantly higher in both Ethiopian (p&lt;0.001) and Vietnamese (p&lt;0.001) patients as compared to the Swedes: choosing Swedish patients as a reference category, the Ethiopian patients had a significant higher expected value of LPS (Coeff.= 140, 95% CI: 122–156), as did the Vietnamese patients (Coeff.=146, 95% CI: 127–164). </plain></SENT>
</text></p><p><text><SENT sid="20828" pm="."><plain>Since it is known that TB may induce increased levels of sCD14 in patients living with HIV-1, we repeated the multivariable analysis after excluding the 24 Vietnamese patients who had ongoing TB (Table 3). </plain></SENT>
<SENT sid="20829" pm="."><plain>Similar results were obtained, although the sCD14 difference also became significant between the Swedish and Ethiopian groups (p&lt;0.05) (Table 3). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="S0004"><title><text><SENT sid="20830" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="20831" pm="."><plain>The present study of patients living with HIV-1 from Vietnam and Ethiopia gives support to the view that MT is an important feature of the HIV-1 disease in LMICs [9]. </plain></SENT>
<SENT sid="20832" pm="."><plain>Thus, the levels of anti-flagellin IgG, LPS and sCD14 were increased in the patients living with HIV-1 from both Vietnam and Ethiopia as compared to HIV-negative controls from the same geographical regions and socioeconomic grouping. </plain></SENT>
<SENT sid="20833" pm="."><plain>Also, patients living with HIV-1 from Vietnam and Ethiopia had higher levels of anti-flagellin IgG and LPS as compared to patients living in Sweden. </plain></SENT>
<SENT sid="20834" pm="."><plain>It can be argued that significant differences existed in, for example, CD4+ T-cells between the patients from the different countries, but the differences also persisted after multivariate analysis (adjusted for age, sex and CD4+ T-cells). </plain></SENT>
<SENT sid="20835" pm="."><plain>It is thus possible that these differences are related to other factors such as different compositions of the gut microbiota and the food intake, poorer hygiene and sanitation and/or frequent exposure to other gastrointestinal infections. </plain></SENT>
<SENT sid="20836" pm="."><plain>Also, another factor that may play an important role for these differences is the viral clade. </plain></SENT>
<SENT sid="20837" pm="."><plain>It is not unreasonable to assume that clade diversity may play an important role in HIV immune activation as a result of MT. </plain></SENT>
<SENT sid="20838" pm="."><plain>Since the viral heterogeneity in our cohorts was limited, the present study did not allow us to evaluate the impact of subtypes on MT. </plain></SENT>
<SENT sid="20839" pm="."><plain>However, it is worth exploring further, and we aim to investigate this aspect in the future. </plain></SENT>
</text></p><p><text><SENT sid="20840" pm="."><plain>Higher levels of MT are likely to result in differences in immune activation and thereby to have a profound effect on the host immune profiles afflicting patients living with HIV-1 in LMICs [10, 13, 14]. </plain></SENT>
<SENT sid="20841" pm="."><plain>In contrast to the LPS and anti-flagellin levels, the sCD14 level was highest in the Vietnamese patients, which could be related to the fact that 30% of them were co-infected with TB, which was not the case for the Ethiopian and Swedish patients. </plain></SENT>
<SENT sid="20842" pm="."><plain>Consistent with these observations, Toossi et al. found that the level of sCD14 in Ugandan patients living with both HIV and TB was higher than in subjects living with HIV only [15]. </plain></SENT>
</text></p><p><text><SENT sid="20843" pm="."><plain>It is well established that effective ART reduces MT and immune activation in patients living with HIV-1 who live in high-income countries [1, 16, 17]. </plain></SENT>
<SENT sid="20844" pm="."><plain>The knowledge concerning patients from LMICs is limited to one South African study reporting that increased MT was found before ART and that it decreased but remained elevated during efficient therapy [11]. </plain></SENT>
<SENT sid="20845" pm="."><plain>In our study, the Vietnamese patients, in whom we had follow-up samples, had undetectable virus after two years of ART [12]. </plain></SENT>
<SENT sid="20846" pm="."><plain>A concomitant decrease in the MT markers was seen, suggesting that ART improves the gut–blood barrier damage also found in patients from these surroundings. </plain></SENT>
</text></p><p><text><SENT sid="20847" pm="."><plain>A subgroup of the Vietnamese patients (n=24) had been treated for two months with tuberculostatics with efficient response. </plain></SENT>
<SENT sid="20848" pm="."><plain>Indeed, we found that these patients had lower anti-flagellin IgG and a tendency to lower LPS. </plain></SENT>
<SENT sid="20849" pm="."><plain>It has been shown that antibiotics decrease the MT in monkeys infected with simian immunodeficiency virus [18], and we have reported that a similar effect is seen in humans living with HIV-1 [8]. </plain></SENT>
<SENT sid="20850" pm="."><plain>It is thus possible that the tuberculostatics had induced changes in the gut microbiota, resulting in a decreased MT. </plain></SENT>
<SENT sid="20851" pm="."><plain>We therefore recommend that any ongoing antibiotic treatment should be considered when MT is studied. </plain></SENT>
<SENT sid="20852" pm="."><plain>In contrast, the sCD14 level was higher than in the patients without tuberculostatics. </plain></SENT>
<SENT sid="20853" pm="."><plain>It is not unlikely that this discrepancy is related to an increased immune activation seen due to remaining disease activity of the TB, since the TB treatment had been given for only two months. </plain></SENT>
<SENT sid="20854" pm="."><plain>Also, we cannot exclude that the increased immune activation was related to other ongoing subclinical OIs. </plain></SENT>
<SENT sid="20855" pm="."><plain>Thus, sCD14 is a biomarker not only for MT but also for other immune activation processes. </plain></SENT>
</text></p><p><text><SENT sid="20856" pm="."><plain>We also analyzed the association between the biomarkers and the clinical outcome. </plain></SENT>
<SENT sid="20857" pm="."><plain>As expected, a higher viral load and lower CD4+ T-cells correlated to an increased mortality. </plain></SENT>
<SENT sid="20858" pm="."><plain>Also, the results were consistent with earlier reports noting that higher levels of sCD14 are associated with a poorer clinical outcome [19, 20]. </plain></SENT>
<SENT sid="20859" pm="."><plain>Consistently, patients who did not develop a new OI or died had significantly lower levels of LPS, anti-flagellin IgG as well as sCD14. </plain></SENT>
<SENT sid="20860" pm="."><plain>This finding is in line with the possibility that a more pronounced MT may lead to increased immune activation with an associated poorer immunological response to other infections, including OIs. </plain></SENT>
</text></p><p><text><SENT sid="20861" pm="."><plain>In conclusion, we showed that treatment-naïve Vietnamese and Ethiopian patients living with HIV have elevated biomarkers of MT as compared to HIV-negative controls from the same geographical regions and also compared to patients living in Sweden. </plain></SENT>
<SENT sid="20862" pm="."><plain>Also, in the Vietnamese patients the MT was reduced following 2 years of ART. </plain></SENT>
<SENT sid="20863" pm="."><plain>Further investigations of the role of MT in patients living with HIV from LMICs can contribute to an increased understanding of the HIV disease in such countries. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusion" id="S0005"><title><text><SENT sid="20864" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="20865" pm="."><plain>The role of MT for HIV disease progression in patients living in resource-limited settings is controversial. </plain></SENT>
<SENT sid="20866" pm="."><plain>This study adds more emerging evidence on the prevalence and role of MT in patients living with HIV-1 in low- (Ethiopia) and middle-income (Vietnam) countries being higher than in patients in a high-income country (Sweden). </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="COMP_INT"><sec id="S0006"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></SecTag><SecTag type="AUTH_CONT"><sec id="S0007"><title>Authors’ contributions</title><p>All authors were involved in the study plan and in reviewing the manuscript. SA performed most of the experiments, data analysis and interpretation of results, and wrote the manuscript together with AS. AS was the principal investigator, and he coordinated and financially supported the study. BB performed laboratory testing of specimens. PN, DDC, WA, ML and LL conceived the study, provided the clinical linkage to the study, reviewed the manuscript and provided comments. GM contributed to the statistical data analysis, reviewed the manuscript and provided useful comments. All authors have read and approved the manuscript.</p></sec></SecTag><SecTag type="ACK_FUND"><sec id="S0008"><title>Funding</title><p><text4fund><text><SENT sid="20867" pm="."><plain>This work was supported by the European and Developing Countries Clinical Trial Partnership, SIDA, the Swedish Civil Contingencies Agency (SWE-2009-151) and the Swedish Research Council (521-2012-3476). </plain></SENT>
</text></text4fund></p></sec></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="CIT0001"><text><SENT sid="20868" pm="."><plain>1BrenchleyJMPriceDASchackerTWAsherTESilvestriGRaoSMicrobial translocation is a cause of systemic immune activation in chronic HIV infectionNat Med20061213657117115046 </plain></SENT>
</text></ref><ref id="CIT0002"><text><SENT sid="20869" pm="."><plain>2AncutaPKamatAKunstmanKJKimEYAutissierPWurcelAMicrobial translocation is associated with increased monocyte activation and dementia in AIDS patientsPLoS One20083e251618575590 </plain></SENT>
</text></ref><ref id="CIT0003"><text><SENT sid="20870" pm="."><plain>3SchoepferAMSchafferTSeibold-SchmidBMullerSSeiboldFAntibodies to flagellin indicate reactivity to bacterial antigens in IBS patientsNeurogastroenterol Motil20082011101818694443 </plain></SENT>
</text></ref><ref id="CIT0004"><text><SENT sid="20871" pm="."><plain>4TarganSRLandersCJYangHLodesMJCongYPapadakisKAAntibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s diseaseGastroenterology20051282020815940634 </plain></SENT>
</text></ref><ref id="CIT0005"><text><SENT sid="20872" pm="."><plain>5LodesMJCongYElsonCOMohamathRLandersCJTarganSRBacterial flagellin is a dominant antigen in Crohn diseaseJ Clin Invest2004113129630615124021 </plain></SENT>
</text></ref><ref id="CIT0006"><text><SENT sid="20873" pm="."><plain>6TroseidMNowakPNystromJLindkvistAAbdurahmanSSonnerborgAElevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapyAIDS2010241733720502315 </plain></SENT>
</text></ref><ref id="CIT0007"><text><SENT sid="20874" pm="."><plain>7NowakPAbdurahmanSLindkvistATroseidMSonnerborgAImpact of HMGB1/TLR ligand complexes on HIV-1 replication: possible role for flagellin during HIV-1 infectionInt J Microbiol2012201226383622719767 </plain></SENT>
</text></ref><ref id="CIT0008"><text><SENT sid="20875" pm="."><plain>8VesterbackaJNowakPBarqashoBAbdurahmanSNystromJNilssonSKinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapyPLoS One20138e5503823383047 </plain></SENT>
</text></ref><ref id="CIT0009"><text><SENT sid="20876" pm="."><plain>9ReddADDabitaoDBreamJHCharvatBLaeyendeckerOKiwanukaNMicrobial translocation, the innate cytokine response, and HIV-1 disease progression in AfricaProc Natl Acad Sci U S A200910667182319357303 </plain></SENT>
</text></ref><ref id="CIT0010"><text><SENT sid="20877" pm="."><plain>10LesterRTYaoXDBallTBMcKinnonLROmangeWRKaulRHIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workersPLoS One20094e564419461969 </plain></SENT>
</text></ref><ref id="CIT0011"><text><SENT sid="20878" pm="."><plain>11CassolEMalfeldSMahashaPvan der MerweSCassolSSeebregtsCPersistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapyJ Infect Dis20102027233320629534 </plain></SENT>
</text></ref><ref id="CIT0012"><text><SENT sid="20879" pm="."><plain>12Cuong doDThorsonASonnerborgAHoaNPChucNTPhucHDSurvival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern VietnamScand J Infect Dis201244201822122590 </plain></SENT>
</text></ref><ref id="CIT0013"><text><SENT sid="20880" pm="."><plain>13El-SadrWMTsiourisSJHIV-associated tuberculosis: diagnostic and treatment challengesSemin Respir Crit Care Med2008295253118810685 </plain></SENT>
</text></ref><ref id="CIT0014"><text><SENT sid="20881" pm="."><plain>14BorkowGBentwichZChronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergyClin Microbiol Rev200417101230table of contents15489359 </plain></SENT>
</text></ref><ref id="CIT0015"><text><SENT sid="20882" pm="."><plain>15ToossiZFunderburgNTSirdeshmukSWhalenCCNantezaMWJohnsonDFSystemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjectsJ Infect Dis20132071841923479321 </plain></SENT>
</text></ref><ref id="CIT0016"><text><SENT sid="20883" pm="."><plain>16BaroncelliSGalluzzoCMPirilloMFManciniMGWeimerLEAndreottiMMicrobial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with&lt;50 copies/ml HIV-1 RNAJ Clin Virol2009463677019782638 </plain></SENT>
</text></ref><ref id="CIT0017"><text><SENT sid="20884" pm="."><plain>17DyeCWilliamsBGThe population dynamics and control of tuberculosisScience20103288566120466923 </plain></SENT>
</text></ref><ref id="CIT0018"><text><SENT sid="20885" pm="."><plain>18McKennaPHoffmannCMinkahNAyePPLacknerALiuZThe macaque gut microbiome in health, lentiviral infection, and chronic enterocolitisPLoS Pathog20084e2018248093 </plain></SENT>
</text></ref><ref id="CIT0019"><text><SENT sid="20886" pm="."><plain>19KullerLHTracyRBellosoWWitSDDrummondFLaneHCInflammatory and coagulation biomarkers and mortality in patients with HIV infectionPLoS Med20085e20318942885 </plain></SENT>
</text></ref><ref id="CIT0020"><text><SENT sid="20887" pm="."><plain>20SandlerNGWandHRoqueALawMNasonMCNixonDEPlasma levels of soluble CD14 independently predict mortality in HIV infectionJ Infect Dis20112037809021252259 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
